ROCKVILLE, Md., July 26, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it received a notice of issuance for patent number 12/710,097 titled: "Transplantation of Human Neural Cells for Treatment of Neurodegenerative Conditions." This patent covers both the culturing of central nervous system cells as well as their transplantation into spinal cord tissue to treat neurodegenerative conditions, including amytrophic lateral sclerosis (ALS or Lou Gehrig's disease). Neuralstem is currently conducting a Phase I safety trial of its human spinal cord stem cells in the treatment of ALS.
"This is a major addition to our patent estate," said Neuralstem Chairman & Chief Scientific Officer, Karl Johe, PhD. "This patent includes claims covering processes for dissociating our neural stem cells from central nervous system tissue; culturing the cells; expanding the cells in vitro and transplanting the neural stem cells into the spinal cord of a patient to treat a wide array of neurodegenerative conditions including, amyotrophic lateral sclerosis (ALS)."
"We are pleased to have this new patent issued, which will expire in Q1 2030," said Neuralstem President & CEO, Richard Garr. "We have currently transplanted 17 patients in our ALS trial and we have been encouraged by the results so far. We are focused on this program as our first potential transplantation product. We believe that having this specific patent coverage as well as this patent life into 2030 is reflective of the value we are creating in our cell therapy programs."
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively in
|SOURCE Neuralstem, Inc.|
Copyright©2012 PR Newswire.
All rights reserved